MBM-55 NEW
| Price | $187 | $313 | $455 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-02 |
Product Details
| Product Name: MBM-55 | CAS No.: 2083622-09-5 |
| Purity: 99.98% | Supply Ability: 10g |
| Release date: 2025/05/02 |
Product Introduction
Bioactivity
| Name | MBM-55 |
| Description | MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. |
| In vitro | MBM-55 (0.5-1 μM; 24 hours) induces G2/M phase arrest and accumulation of cells with >4N content in HCT-116 cells. MBM-55 (0.5-1 μM; 24 hours) causes cell apoptosis in a concentration-dependent manner in HCT-116 cells.MBM-55 inhibits MGC-803, HCT-116, Bel-7402 cells proliferation with IC50s of 0.53, 0.84, 7.13 μM, respectively[1]. |
| In vivo | In female BALB/c nu/nu mice bearing HCT-116 xenografts, MBM-55 (20 mg/kg; i.p.) exhibits good antitumor activity and a well-tolerated dose schedule. MBM-55 (1.0 mg/kg; i.v.) shows the CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 120 mg/mL (240.70 mM), Sonication is recommended. |
| Keywords | selectivity | S6Kinase | S6 Kinase | RSK1 | proliferation | Nek2 | NEK2 | MBM-55 | MBM55 | MBM 55 | Inhibitor | inhibit | GSK-3β | GSK3 | DYRK1a | cycle | CHK1 | cell | CDK4 | CDK2 | BcrAbl | AuroraKinase | Aurora Kinase | Aurora A | arrest | Apoptosis | antitumor | AKT1 | ABL |
| Inhibitors Related | Ribociclib | Ethyl gallate | Abemaciclib | CHIR-99021 | sodium lauroyl-α-hydroxyethyl sulfonate | 4-Chloro-2'-bromoacetophenone | Artemisinin | CASIN | Imatinib | 2,3-Butanediol | Sodium salicylate | Dinaciclib |
| Related Compound Libraries | Glycolysis Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Angiogenesis related Compound Library | Neuroprotective Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $195.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-06-12 | |
| $1670.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $187.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-04-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY